arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

BIOMERICA INC

BMRA
$1.68 ▼ -0.02 (-1.18%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
65 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOMERICA INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.5M
Dividend Yield —
Revenue Growth -8.3% ↘
Op. Margin -97.0% ↗
ROIC -33.8% ↗
FCF / Share $-0.24
Trailing P/E —
Price / Book 2.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 4, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.26M
↓ -8.3% —
Net Income Profit after all expenses
$-1.23M
↓ -7.6% —
Operating Margin Operating profit as % of sales
-97.0%
↑ +44.6% 0th
FCF / Share Free cash flow per share
$-0.24
↓ -139.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↓
4
Cash Quality ↑
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 65 quarters